Boston Scientific Past Earnings Performance
Past criteria checks 4/6
Boston Scientific's earnings have been declining at an average annual rate of -21%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 9.1% per year. Boston Scientific's return on equity is 8.5%, and it has net margins of 11.3%.
Key information
-21.0%
Earnings growth rate
-22.4%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 9.1% |
| Return on equity | 8.5% |
| Net Margin | 11.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Do Boston Scientific's (NYSE:BSX) Earnings Warrant Your Attention?
Dec 19
Why The Fundamentals Make Me Bullish On Boston Scientific
Oct 31Boston Scientific Q3: Good Growth, But Not Good Enough To Justify Its P/E Ratio
Oct 23Is Boston Scientific (NYSE:BSX) A Risky Investment?
Oct 10Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement
Sep 24Boston Scientific: Forward Returns Are Likely To Be Disappointing For Investors
Sep 20Boston Scientific Corporation's (NYSE:BSX) P/E Still Appears To Be Reasonable
Sep 09A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 23The Strong Earnings Posted By Boston Scientific (NYSE:BSX) Are A Good Indication Of The Strength Of The Business
Aug 08Boston Scientific Q2 Earnings Preview: Can The Rally Continue?
Jul 17Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching
Jul 05Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?
Jun 21Boston Scientific Has Become A Standout Growth Story In Med-Tech
Jun 13Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price
Jun 08Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return
Apr 22Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash
Apr 05A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Mar 26We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease
Feb 29What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E
Feb 15Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital
Jan 19Boston Scientific: Portfolio Updates Driving Top-Line Growth
Jan 17Boston Scientific: Continued M&A Drives More Growth
Jan 10Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue
Oct 30ADVENT Offers Up An Early Present For Boston Scientific Investors
Aug 28Boston Scientific Remains Operationally Sound But May Have Limited Upside
Jul 14Revenue & Expenses Breakdown
How Boston Scientific makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 15,911 | 1,793 | 5,751 | 1,519 |
| 30 Jun 24 | 15,229 | 1,828 | 5,430 | 1,468 |
| 31 Mar 24 | 14,707 | 1,765 | 5,339 | 1,443 |
| 31 Dec 23 | 14,240 | 1,570 | 5,190 | 1,414 |
| 30 Sep 23 | 13,757 | 1,191 | 4,974 | 1,381 |
| 30 Jun 23 | 13,400 | 861 | 4,865 | 1,364 |
| 31 Mar 23 | 13,045 | 846 | 4,675 | 1,341 |
| 31 Dec 22 | 12,682 | 642 | 4,520 | 1,323 |
| 30 Sep 22 | 12,567 | 596 | 4,510 | 1,313 |
| 30 Jun 22 | 12,329 | 828 | 4,445 | 1,284 |
| 31 Mar 22 | 12,162 | 754 | 4,400 | 1,247 |
| 31 Dec 21 | 11,888 | 985 | 4,359 | 1,204 |
| 30 Sep 21 | 11,470 | 1,101 | 4,182 | 1,166 |
| 30 Jun 21 | 11,196 | 526 | 4,099 | 1,171 |
| 31 Mar 21 | 10,122 | 201 | 3,777 | 1,115 |
| 31 Dec 20 | 9,913 | -115 | 3,787 | 1,143 |
| 30 Sep 20 | 10,108 | 3,685 | 3,864 | 1,165 |
| 30 Jun 20 | 10,157 | 3,980 | 3,892 | 1,157 |
| 31 Mar 20 | 10,785 | 4,287 | 4,062 | 1,194 |
| 31 Dec 19 | 10,735 | 4,700 | 3,928 | 1,174 |
| 30 Sep 19 | 10,392 | 1,090 | 3,790 | 1,154 |
| 30 Jun 19 | 10,077 | 1,396 | 3,648 | 1,136 |
| 31 Mar 19 | 9,937 | 1,797 | 3,566 | 1,132 |
| 31 Dec 18 | 9,823 | 1,671 | 3,557 | 1,113 |
| 30 Sep 18 | 9,670 | 670 | 3,498 | 1,088 |
| 30 Jun 18 | 9,500 | 521 | 3,424 | 1,053 |
| 31 Mar 18 | 9,267 | 112 | 3,350 | 1,023 |
| 31 Dec 17 | 9,048 | 104 | 3,281 | 997 |
| 30 Sep 17 | 8,831 | 843 | 3,227 | 990 |
| 30 Jun 17 | 8,714 | 788 | 3,199 | 969 |
| 31 Mar 17 | 8,582 | 435 | 3,163 | 945 |
| 31 Dec 16 | 8,386 | 347 | 3,083 | 920 |
| 30 Sep 16 | 8,095 | 81 | 3,029 | 908 |
| 30 Jun 16 | 7,878 | -345 | 2,979 | 895 |
| 31 Mar 16 | 7,595 | -36 | 2,898 | 894 |
| 31 Dec 15 | 7,477 | -239 | 2,847 | 876 |
| 30 Sep 15 | 7,314 | -396 | 2,819 | 840 |
| 30 Jun 15 | 7,272 | -155 | 2,836 | 832 |
| 31 Mar 15 | 7,302 | -253 | 2,883 | 818 |
| 31 Dec 14 | 7,308 | -119 | 2,878 | 817 |
| 30 Sep 14 | 7,258 | 288 | 2,849 | 826 |
| 30 Jun 14 | 7,147 | 240 | 2,766 | 831 |
| 31 Mar 14 | 7,083 | 366 | 2,680 | 848 |
| 31 Dec 13 | 7,070 | -121 | 2,651 | 861 |
Quality Earnings: BSX has high quality earnings.
Growing Profit Margin: BSX's current net profit margins (11.3%) are higher than last year (8.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BSX's earnings have declined by 21% per year over the past 5 years.
Accelerating Growth: BSX's earnings growth over the past year (50.5%) exceeds its 5-year average (-21% per year).
Earnings vs Industry: BSX earnings growth over the past year (50.5%) exceeded the Medical Equipment industry 12.9%.
Return on Equity
High ROE: BSX's Return on Equity (8.5%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 10:49 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Boston Scientific Corporation is covered by 70 analysts. 32 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| David Rescott | Baird |
| Ishan Majumdar | Baptista Research |